

Prior Authorization Request

HARVONI (ledipasvir - sofosbuvir)

Instructions

Plan Member Signature

Please complete Part A and have your physician complete Part B. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. Please note that you have the right to appeal the decision made by Express Scripts Canada.

Part A - Patient Patient information First Name: Last Name: Insurance Carrier Name/Number: Group Number: Client ID: Date of Birth (YYYY/MM/DD): Relationship: | Employee | Spouse | Dependent Language: English French Gender: | | Male | | Female Address: City: Province: Postal Code: Email address: Telephone (home): Telephone (cell): Telephone (work): Coordination of benefits **Patient** Is the patient enrolled in any patient assistance program? Yes No **Assistance Program** Contact Name: _ Has the patient applied for reimbursement under a provincial plan? Yes No N/A **Provincial** Coverage What is the coverage decision of the drug? Approved Denied *Attach decision letter* Has the patient applied for reimbursement under a primary plan? Yes No N/A **Primary** Coverage What is the coverage decision of the drug? Approved Denied *Attach decision letter* Authorization On behalf of myself and my eligible dependents, I authorize my group benefit provider, and its agents, to exchange the personal information contained on this form. I give my consent on the understanding that the information will be used solely for purposes of administration and management of my group benefit plan. This consent shall continue so long as my dependents and I are covered by, or are claiming benefits under the present group contract, or any modification, renewal, or reinstatement thereof.

Date



Prior Authorization Request

HARVONI (ledipasvir - sofosbuvir)

Part B - Prescriber

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

HARVONI (ledipasvir – sofosbuvir)		☐ New request ☐ Renewal request*		
Dose	Administration (ex: oral, IV, etc)	Frequency	Duration	
Site of drug administration:				
	an's office/Infusion clinic	Hospital (outpatient)	Hospital (inpatient)	
* Please submit proof of prior	coverage if available	-		
ECTION 2 – ELIGIBILITY	CRITERIA			
1. Please indicate if the pati	ent satisfies the below criteria:			
Hepatitis C Virus - Adult - 8 v	veek approval			
·	veek approval chronic hepatitis C virus (HCV) infec	ction in an adult, AND		
For the treatment of			mL	
For the treatment of	chronic hepatitis C virus (HCV) infec		mL	
For the treatment of the patient is treatment.	chronic hepatitis C virus (HCV) infecent-naïve with a pre-treatment HCV		mL	
For the treatment of the patient is treatment. The patient is treatment. Hepatitis C Virus – Pediatric –	chronic hepatitis C virus (HCV) infecent-naïve with a pre-treatment HCV	RNA less than 6 million IU/I		
For the treatment of one of the patient is treatment. Hepatitis C Virus – Pediatric – For the treatment of one of the treatment.	chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infections.	RNA less than 6 million IU/I		
For the treatment of the patient is treatment. The patient is treatment. Hepatitis C Virus – Pediatric – For the treatment of the patient is 12 to 1	chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infec	RNA less than 6 million IU/I		
For the treatment of one of the patient is treatment. Hepatitis C Virus – Pediatric – For the treatment of one of the treatment.	chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infec	RNA less than 6 million IU/I		
The patient is treatment. Hepatitis C Virus – Pediatric – For the treatment of one of the patient is 12 to 1. The patient has geno	chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infec	RNA less than 6 million IU/I		
For the treatment of one of the patient is treatment. Hepatitis C Virus – Pediatric – For the treatment of one of the patient is 12 to 1. The patient has genous OR	chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infection infection	RNA less than 6 million IU/I		
For the treatment of one of the patient is treatment. Hepatitis C Virus – Pediatric – For the treatment of one of the patient is 12 to 1. The patient has geno	chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infection infection	RNA less than 6 million IU/I		
For the treatment of one of the patient is treatment. Hepatitis C Virus – Pediatric – For the treatment of one of the patient is 12 to 1. The patient has genous OR	chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infection in the chronic hepatitis C virus (HCV) infection infection in the chronic hepatitis C virus (HCV) infection infection in the chronic hepatitis C virus (HCV) infection in the chronic hepatitis	RNA less than 6 million IU/I		



Prior Authorization Request

HARVONI (ledipasvir – sofosbuvir)

Drug	Dosage and administration	Duration of therapy		Reason for cessation	
		From	То	Inadequate response	Allergy/ Intolerance

SECTION 3 - PRESCRIBER INFORMATION

Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

Please fax or mail the completed form to Express Scripts Canada®

Fax: Express Scripts Canada Clinical Services 1 (855) 712-6329

Mail: Express Scripts Canada Clinical Services 5770 Hurontario Street, 10th Floor Mississauga, ON L5R 3G5